InnoCan Pharma (INNO) AI Stock Analysis

• Market Cap: C$46.42M
• Dividend Yield: N/A
• Average Volume (3M): 15.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.35
• Revenue Growth: 118.36%
• EPS Growth: 63.01%
• Country: CA
• Employees: 11
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 290,115,500
• 10 Day Avg. Volume: 14,478
• 30 Day Avg. Volume: 15,259
• PEG Ratio: -0.34
• Price to Book (P/B): 8.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

InnoCan Pharma demonstrates robust revenue growth and strategic advancements, but significant profitability challenges and bearish technical indicators pose risks. While corporate events signal potential, the financial struggles and negative valuation metrics are concerning.

InnoCan Pharma Business Overview & Revenue Model

Company Description

InnoCan Pharma (INNO) is a pharmaceutical company focused on developing innovative therapeutic solutions leveraging cannabinoid science. It operates primarily in the biotechnology and pharmaceutical sectors, with a core emphasis on the research and development of novel drug delivery systems and pharmaceutical products. InnoCan Pharma is engaged in creating advanced topical treatments, unique delivery platforms, and therapies that harness the therapeutic potential of cannabinoids to address various medical needs.

How the Company Makes Money

InnoCan Pharma generates revenue through the development and commercialization of its proprietary drug delivery systems and pharmaceutical products. The company primarily makes money by licensing its technology to other pharmaceutical companies and forming strategic partnerships to co-develop and market its innovations. Additionally, InnoCan Pharma engages in direct sales of its therapeutic products and topical treatments to healthcare providers and distributors. Collaborations with research institutions and government agencies for funded projects also contribute to its revenue streams.

InnoCan Pharma Financial Statement Overview

Summary

InnoCan Pharma is on a growth trajectory with increasing revenues but is yet to achieve profitability, as reflected in negative margins. The balance sheet shows a strong equity position with low leverage, suggesting financial resilience. However, cash flow challenges persist, indicating a need for operational improvements to support sustainable growth.

Income Statement

InnoCan Pharma has demonstrated substantial revenue growth with a notable increase from previous periods, reflecting a strong recovery trajectory. However, persistent negative net income and EBIT margins indicate challenges in achieving profitability. The negative EBITDA suggests ongoing operational difficulties.

Balance Sheet

The company maintains a strong equity base with an improving equity ratio, suggesting financial stability. A very low debt-to-equity ratio indicates minimal leverage, reducing financial risk. However, high liability levels relative to assets could suggest future liquidity concerns.

Cash Flow

InnoCan Pharma faces challenges with negative free cash flow and operating cash flow, indicating cash generation issues. The operating cash flow to net income ratio shows inefficiencies in translating earnings into cash. Financing activities have been crucial in sustaining operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
28.93M	13.66M	2.56M	196.00K	8.00K	0.00
	Gross Profit
26.07M	11.98M	2.11M	121.00K	3.00K	0.00
	EBIT
-1.22M	3.80M	-6.27M	-7.48M	-4.72M	-3.00M
	EBITDA
-836.00K	-3.77M	-3.85M	-10.04M	-9.90M	-2.98M
	Net Income Common Stockholders
-2.60M	-4.70M	-3.89M	-10.06M	-15.18M	-3.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
214.00K	3.88M	4.95M	11.05M	2.34M	1.97M
	Total Assets
660.00K	6.94M	6.98M	12.57M	4.33M	2.58M
	Total Debt
0.00	33.00K	34.00K	1.00K	38.00K	72.00K
	Net Debt
-214.00K	-3.85M	-4.91M	-11.05M	-2.30M	-1.90M
	Total Liabilities
533.00K	2.55M	751.00K	3.56M	7.94M	1.17M
	Stockholders Equity
127.00K	4.10M	6.39M	9.05M	-3.61M	1.41M
Cash Flow		Free Cash Flow
-2.41M	-3.95M	-6.09M	-6.67M	-3.69M	-2.72M
	Operating Cash Flow
-2.39M	-3.90M	-6.07M	-6.63M	-3.69M	-2.71M
	Investing Cash Flow
-20.00K	-84.00K	-31.00K	-48.00K	0.00	-9.00K
	Financing Cash Flow
3.42M	2.92M	125.00K	15.30M	4.02M	4.45M

InnoCan Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:INNO, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.18, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.98 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:INNO.

InnoCan Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDP	71 Outperform	C$83.23M	13.25	11.27%	―	-3.82%	-50.36%
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
MPH	52 Neutral	C$9.81M	―	-5.11%	―	0.98%	-13.31%
INNO	47 Neutral	C$46.42M	―	-39.57%	―	118.36%	63.01%
RVV	46 Neutral	C$10.46M	―	-66.49%	―	―	-4.84%
BNXT	37 Underperform	$60.10M	―	87.69%	―	-89.20%	56.08%
MVMD	35 Underperform	C$8.81M	―	-44.58%	―	-48.33%	47.56%

InnoCan Pharma Corporate Events

Innocan Pharma Secures First Mexican Patent for Cannabis-Based Pain Relief

Innocan Pharma has been granted its first patent in Mexico for a proprietary cannabis-based topical pain relief formulation, marking a significant milestone in its intellectual property portfolio. This approval positions the company for strategic entry into Latin American markets, complementing existing patents in the United States, Russia, and Ukraine, and underscores its leadership in cannabidiol-based wellness innovation.

Innocan Pharma Closes Private Placement to Bolster Operations

Innocan Pharma Corporation has successfully closed a non-brokered private placement offering, raising gross proceeds of $214,839 through the issuance of 1,193,551 units. Each unit consists of one common share and one warrant, with the proceeds intended for working capital and general corporate purposes. This move underscores investor confidence in Innocan’s proprietary technology and is expected to support the company’s ongoing operations and strategic initiatives.

Innocan Pharma Expands IP in Asia and Announces Private Placement

Innocan Pharma has filed a divisional patent application in China for its liposome-based CBD technology, aiming to expand its intellectual property protection in Asia’s rapidly growing pharmaceutical market. Additionally, the company announced a private placement of units to raise CAD $150,000 for working capital and general corporate purposes.

Innocan Pharma’s 2024 Revenue Surges Amid Strategic Growth

Innocan Pharma reported a significant increase in revenues for 2024, with a 114.6% rise to $29.4 million, driven by strong sales from its subsidiary, BI Sky Global Ltd. The company’s financial performance reflects its strategic focus on innovative drug delivery technologies and its commitment to expanding its presence in the beauty and personal care industry, providing growing value to shareholders.

Innocan Pharma Announces $1 Million Debenture Offering to Tamar Innovest

Innocan Pharma has announced a private placement offering of a debenture unit to its largest shareholder, Tamar Innovest, for gross proceeds of $1,000,000. This offering includes a secured convertible debenture and common share purchase warrants, with the proceeds intended for working capital and general corporate purposes. The transaction, classified as a ‘related party transaction,’ highlights Tamar Innovest’s continued support and confidence in Innocan’s vision and strategy, potentially strengthening Innocan’s financial position and market presence.